

1 **Prevalence and determinants of chronic respiratory diseases in adults in**
2 **Khartoum State, Sudan**

3

4 Rana Ahmed¹, Nada Osman^{1,2}, Bandar Noory¹, Rashid Osman¹, Hana
5 ElHassan¹, Hind Eltigani¹, Rebecca Nightingale³, Andre FS Amaral⁴, Jaymini
6 Patel⁴, Peter G. Burney⁴, Kevin Mortimer^{5,6} Asma ElSony^{1,7}

7

8 ¹The Epidemiological Laboratory, Khartoum, Sudan

9 ²Federal Ministry of Health, Sudan

10 ³Liverpool School of Tropical Medicine, Liverpool, UK

11 ⁴National Heart and Lung Institute, Imperial College, London, UK

12 ⁵Liverpool University Hospitals NHS foundation Trust, Liverpool, UK

13 ⁶University of Cambridge, Cambridge, UK

14 ⁷Global Alliance for Respiratory Diseases, Africa Representative

15

16 Running head: Chronic Respiratory Disease in adults, Sudan

17 Word count of the summary: 198

18 Word count of the text: 2909

19 Number of references: 35

20 Number of tables: 3

21 Number of figures: 2

22

23 Correspondence and requests for reprints: Asma El Sony

24 Director, Head of Scientific Activities at the Epidemiological Laboratory, a

25 WHO/EMRO Collaborating Centre for TB and Lung Diseases, PO Box 10012,

26 Khartoum,

27 Phone/Fax: +24 91 5515 2445

28 E-mail: asmaelsony@gmail.com

29

30

31 **SUMMARY**

32 **Background**

33 Chronic respiratory diseases are considered a significant cause of morbidity
34 and mortality worldwide, although data from Africa are limited. This study
35 aimed to determine the prevalence and determinants of chronic respiratory
36 diseases in Khartoum, Sudan.

37 **Methods**

38 Data was collected from 516 participants, aged ≥ 40 , who had completed a
39 questionnaire and undertook pre- and post-bronchodilator spirometry testing.
40 Trained field workers conducted questionnaires and spirometry. Survey-
41 weighted prevalence of respiratory symptoms and spirometric abnormalities
42 were estimated. Regression analysis models were used to identify risk factors
43 for chronic lung diseases.

44 **Results**

45 Using the NHANESIII reference equations, the prevalence of Chronic Airflow
46 Obstruction (CAO) was 10%. The main risk factor was older age 60-69 years
47 (Odds ratio 3.16, 95% Confidence Interval 1.20 – 8.31). Lower education, high
48 body mass index and a history of tuberculosis were also identified as
49 significant risk factors. The prevalence of a low forced vital capacity (FVC)
50 using NHANES III was 62.7% [SE 2.2] and 11.3% [SE 1.4] using locally
51 derived values.

52 **Conclusion**

53 The prevalence of spirometric abnormality mainly (low FVC); was high
54 suggesting that chronic respiratory disease is of substantial public health
55 importance in urban Sudan. Strategies for the prevention and control of these
56 problems are needed.

57

58 Keywords: COPD, CAO, Risk factors, low FVC, SSA

59

60

61

62 The Global Burden of Disease Study estimates 3.9 million deaths annually
63 from chronic non-communicable respiratory diseases – mainly chronic
64 obstructive pulmonary disease (COPD) and asthma^{1,2}. It's burden of deaths
65 and morbidity is expected to increase over future decades especially in low-
66 income and middle-income countries (LMICs)^{3,4}.

67 Prevalence estimates for COPD in sub-Saharan Africa (SSA)^{5,6} are based on
68 limited epidemiological data which lack a standardized definition of COPD. A
69 recent systematic review reported a population prevalence of COPD in SSA
70 ranging from 1.7% to 24.8%⁷.

71 The prevalence and determinants of low FVC in SSA are barely understood
72 however, its reported that Africans have reduced FVC compared with the
73 Caucasian⁸. Moreover, studies reported an association between lung
74 restriction and mortality and a higher prevalence of Chronic Respiratory
75 Disease (CRD) in SSA that linked to numerous risk factors including early
76 childhood exposures, poverty, biomass fuel exposure, smoking and
77 pulmonary tuberculosis (TB)⁹.

78

79 The Burden of Obstructive Lung Disease (BOLD) Initiative developed
80 standardized methods for estimating the burden and determinants of chronic
81 airflow obstruction (CAO) in populations aged 40 years and older^{10,11}. We did
82 a BOLD study in Khartoum, Sudan to help fill the knowledge gap about the
83 chronic respiratory diseases in Africa.

84

85

86 **METHODS**

87 *Setting*

88 Sudan's capital, Khartoum, is made up of 7 localities, across which there is a
89 mix of urban, semi-urban, rural, and internally displaced populations.

90

91 *Sampling*

92 Three localities, with a total population of 661,617, were randomly selected for
93 sampling in this study and divided into clusters. Then 280, 258 and 158
94 households were randomly selected from Jabelawlya, Shargalneel and
95 Omdurman localities respectively.

96

97 *Participants*

98 Using the BOLD protocol¹¹, we approached 998 participants from which 600 ≥
99 40 years old were included using a 3-stage stratified cluster sampling plan.
100 Potential participants who were institutionalized or medically unfit to perform
101 spirometry were excluded.

102

103 *Data collection and management*

104 All study participants completed a structured interview in the local Arabic
105 language administered by trained interviewers. Anthropometric
106 measurements along with pre-bronchodilator and post-bronchodilator
107 spirometry data were collected following the American Thoracic Society (ATS)
108 guidelines using the Easy One system (ndd Medizintechnik, Zurich,
109 Switzerland) by three trained certified technicians¹¹. A minimal data or refusal
110 questionnaire was filled out for those not willing to participate in the full study.
111 The clinical data obtained included height, weight, pulse rate and waist and
112 hip circumference. Quality control was carried out at the BOLD coordinating
113 centre. Usable spirometry was defined as two or more acceptable blows, with
114 FEV₁ and FVC repeatability within 200 mL. Acceptable manoeuvres were
115 defined as those with a rapid start (back-extrapolated volume, 150 mL or 5%
116 of the FVC), lack of cough during the first second, and a small end-of-test
117 volume (<40 mL during the final second). The calibration of all spirometers

118 was verified to be accurate within 3.0% using a 3.00 L syringe at the
119 beginning of each day of testing. Spirometry traces were then classified
120 according to $FEV_1/FVC < \text{lower limit of normality (LLN)}$.

121 CAO was defined by post-bronchodilator (BD) $FEV_1/FVC < \text{LLN}$. Predicted
122 values based on standardized values for age, sex, and height were calculated
123 based on the Third National Health and Nutrition Examination Survey 1988–
124 1994 (NHANES III) of white Americans¹². Local values were derived from
125 spirometry of non-smoking Sudanese adults with no respiratory symptoms or
126 diagnoses participating in this survey. CAO stages were categorised as: stage
127 1 or higher CAO (Post-BD $FEV_1/FVC < \text{LLN}$) and stage 2 or higher CAO
128 (Post-BD $FEV_1/FVC < \text{LLN}$ and post-BD $FEV_1 < 80\%$ predicted).

129

130 *Statistical analysis*

131 Evaluation of selection bias and a comparison between groups was
132 conducted using a chi-square test between participants who completed full
133 data and minimal questionnaires with acceptable or unacceptable spirometry
134 readings. Prevalence estimates of spirometric abnormalities stratified by age
135 and sex were reported using the NHANES III¹¹. Prevalence estimates using
136 locally derived spirometry were also reported.

137 Univariable and multivariable logistic regression analyses were used to test
138 associations between spirometry abnormalities and several exposure
139 variables, including age, sex, education level, self-reported history of
140 tuberculosis (TB), hypertension, diabetes, heart disease, body mass index,
141 smoking status, smoking pack-years, exposure to indoor smoke from biomass
142 fuel and occupational exposure.

143 A wealth score was developed based on the Mokken scale, to differentiate
144 between different levels of wealth using a count of owned assets^{13,14}.

145 Multivariable logistic regression models that included sex, age and all
146 variables from the univariable analysis with a p -value < 0.2 were then
147 developed. The prevalence of respiratory symptoms was reported and
148 associations with the study variables were tested using regression analysis. A
149 description of the associations between abnormal spirometry and respiratory

150 symptoms was reported. The data were analysed using Stata IC 14
151 (StataCorp, College Station, TX). Prevalence estimates and regression
152 models were developed using survey weighting with the Svy package in Stata
153 (14).

154

155 *Ethical considerations*

156 Written informed consent was collected from study participants before data
157 collection. Ethical approval was obtained from the Imperial College London
158 and Khartoum state Ministry of Health.

159

160 **RESULTS**

161 The flow of participants through the study is shown in Figure 1. Of the 998
162 participants approached, 516 provided full questionnaire data and had BOLD
163 centre-approved spirometry results. Eleven of the 998 participants declined to
164 participate fully in the study but completed the minimal data questionnaire.
165 The final response rate was 85.5% (n=696).

166

167 *Participant characteristics*

168 These are presented in Table 1. The mean age was 53.8 years (SD 10.4) and
169 59.3% were men. Overall, 35% completed primary school. Men had a higher
170 level of education, as did the group aged 40-49 years when compared to
171 other age groups. The mean number of household members was 7.8
172 (SD3.56) and the mean wealth score was 5.2 (SD 2.7).

173 Among respondents, 24% had smoked cigarettes while 50% of men were
174 current smokers. About 24% of smokers had more than a 20 pack-years of
175 exposure. Exposure to indoor biomass fuel for ≥ 6 months was reported by
176 82% of participants. In total, 78% reported having used an indoor open fire
177 fuelled by coal or charcoal for cooking for ≥ 6 months, while 35% used
178 firewood and 21% used kerosene. Overall, women had a higher mean
179 number of hours of exposure to indoor biomass fuel per year than men (70%
180 vs. 54%). Farming was the most reported occupation (in 24%, Table 1).

181 In total, 23% of participants were obese and 7% were underweight.
182 Hypertension was self-reported by 20% of all participants, of whom 55% were
183 women. Diabetes was reported by 9% (9.5% of women and 8.8% of men).

184

185 *Respiratory symptoms*

186 At least one respiratory symptom was reported by 23% (Standard error (SE)
187 1.9) of participants; respiratory symptoms interfering with daily activities were
188 reported by 1.9% (SE 0.5). Cough was reported by 10.4% (SE 1.3), with the
189 highest prevalence recorded in participants aged 70+ years (11.9% [SE 4.9]).
190 Chronic cough (lasting for more than 3 months per year) was reported by
191 4.0% (SE 0.8). Production of sputum was reported by 11% (SE 1.3) and
192 chronic production of sputum (for more than 3 months per year) was reported
193 by 5% (SE 0.09). Shortness of breath was reported by 11% (SE 1.3) and 41%
194 (SE 6.5) of this group reported that breathing problems made it difficult to walk
195 more than 100 yards. Wheeze in the past 12 months in the absence of cold
196 was the least commonly reported symptom (3.0% [SE 0.7], Supplementary
197 Table S1).

198

199 *Spirometry*

200 No statistically significant differences were found between the groups who did
201 or did not complete the spirometry test. Using NHANES III, stage 1 or higher
202 CAO prevalence was 10.3% [SE 1.4] (9.2 [SE 1.7] of men and 11.2 [SE 2.4]
203 of women). Using the locally derived reference range the prevalence was
204 5.7% [SE 1.1] (5.2% [SE 1.3] of men and 6.2 [SE 1.9] of women).

205 Participants aged 60-69 years had the highest prevalence of stage 1 or higher
206 CAO (13.4% [SE 3.8]). Prevalence of stage 2 or higher CAO was 9.4% [SE
207 1.4] (8.8% [SE 1.7] of men and 10.1% [SE 2.2] of women). Using the locally
208 derived reference range, 3.0% [SE 0.8] of the study population had stage 2 or
209 higher CAO (2.9% [SE 0.9] of men and 3.1% [SE 1.3] of women). Similarly,
210 participants aged 60-69 years had the highest prevalence of stage 2 or higher
211 CAO using both the local and NHANES reference ranges (17.6% [SE 4.2] vs.
212 6.7% [SE 2.6]).

213 Low FVC was seen in 62.7% [SE 2.2] (65.2% [SE 2.8] in men vs. 59.8% [SE
214 3.5] in women). Cough was less reported in those with low FVC (OR 0.48,
215 95% CI 0.27 - 0.87).

216 Airflow reversibility was found in 6.1% [SE 1.1] of the total study population
217 and was more common in women than men (8% [SE 1.9] vs. 4.4% [SE 1.1]).
218 Airflow obstruction persisted after use of a bronchodilator in 8.4% (SE 4.7) of
219 participants with reversibility. (Supplementary Table S2, Figure 2).

220

221 *Factors associated with respiratory symptoms*

222 In both univariable and multivariable analyses, chronic production of sputum
223 was negatively associated with age (Supplementary Tables S3 and S4).
224 Participants aged 60-69 years were less likely to report chronic sputum
225 production (OR 0.39, 95% CI 0.16 - 0.93) than those aged 40-49 years. There
226 was a significantly increased likelihood of regular sputum production with
227 being an ex-smoker (OR 2.66, 95% CI 1.09 - 6.50) and having diabetes (OR
228 4.04, 95% CI 1.82 - 8.96). Participants with lower socioeconomic status; who
229 have a wealth score of 2 tend to have higher odds of sputum production
230 compared to those with zero score (OR 7.18, 95% CI 1.16 - 44.53).

231 In multivariable analysis, the likelihood of having shortness of breath was
232 significantly greater in participants exposed to indoor biomass fuel (OR 4.56,
233 95% CI 1.44 - 14.43). The presence of wheeze was only associated with
234 being a current smoker (OR 3.49, 95% CI 1.02 - 11.96). There were no
235 significant associations between CAO and respiratory symptoms.

236

237 *Factors associated with post-bronchodilator airway obstruction*

238 Participants aged 60-69 years had the highest risks of CAO stage 1 or higher
239 (OR 3.16, 95% CI 1.20 - 8.31) and stage 2 or higher (OR 3.39, 95% CI 1.04 -
240 6.93) than those aged 40-49 years. In contrast, having higher education level
241 was protective against any obstruction in bivariate analysis (OR 0.31, 95% CI
242 0.13 - 0.76), however no association was identified after adjustment. Similarly,
243 being overweight or obese was protective against any obstruction (OR 0.38,

244 95% CI 0.17 - 0.82 and OR 0.34, 95% CI 0.13 - 0.99, respectively). Those
245 with a history of TB were less likely to have any obstruction (OR 0.08, 95% CI
246 0.01 - 0.59). There was no observed trend in Mokken scale points and CAO.
247 However, participants with a low socioeconomic position who scored ≥ 2 in
248 wealth score had the highest odds of developing stage 1 or higher and stage
249 2 or higher CAO (OR 6.00, 95% CI 1.03 - 34.94). No other factor was
250 significantly associated with airway obstruction (Table 2, Supplementary
251 Tables S5 and S6).

252 Using the local reference range, participants aged 60-69 years were more
253 likely to have CAO stage 1 or higher than their younger counterparts (OR
254 3.10, 95% CI 1.01 - 9.57), and being obese were negatively associated with
255 obstruction (OR 0.29, 95% CI 0.09 - 0.97) in multivariable analysis. A higher
256 education level was protective against CAO in the bivariate analysis (OR 0.23,
257 95% CI 0.063 - 0.83) however no association was identified after adjustment.

258

259 *Factors associated with low FVC*

260 Using the NHANES III, low FVC was associated with smoking 10-20 packs
261 year history, having primary or higher-level education, having more people in
262 house and being obese (OR 2.79, 95% CI 1.11 - 7.00; OR 2.42, 95% CI 1.43 -
263 4.09; OR 0.94, 95% CI 0.89 - 0.99 and OR 1.73, 95% CI 1.04 - 2.86
264 respectively) in bivariate analysis. In multivariate analysis, those aged 50-59
265 were less likely to have low FVC compared to those aged 40-49 years (OR
266 0.50, 95%CI 0.31 - 0.81). No other factors were associated with low FVC in
267 multivariate analysis (Table 3).

268

269 **DISCUSSION**

270

271 This population-based survey aimed to investigate the prevalence and
272 determinants of chronic respiratory diseases in the population aged ≥ 40 years
273 in urban Sudan. Our main finding was that approximately 10% of people in
274 this age group had CAO. CAO stage II or higher was detected in 9.4% of the
275 overall population using the same reference range, though this decreased to
276 3.0% when the local reference range was used.

277 A higher prevalence of obstruction when using the NHANES III compared to
278 the local reference range has been reported previously⁹. In spite of being the
279 only available data, values of the local methodology might be more ethnically
280 suitable compared to NHANES III. However, different exposures in this setting
281 may constrain its use^{9,15}.

282 The determined prevalence of spirometric obstruction is consistent with that in
283 similar studies from sub-Saharan Africa, where the prevalence of smoking is
284 high¹⁶. Previous BOLD studies reported COPD prevalence of 23% in men and
285 16.9% in women in South Africa¹⁷ and 7.7% in Nigeria^{7,18,19}. CAO prevalence
286 reported from a multinational BOLD study was 11.5% in men and 8.8% in
287 women which is consistent with our findings²⁰. Compared to studies from the
288 MENA region (Middle East and North Africa), our findings are higher than
289 those in Saudi Arabia²¹, Tunisia^{22,23}, Morocco²⁴, Algeria²⁵ and Lebanon²⁶.

290 Older age was the main risk factor for CAO in our study, which is consistent
291 with both regional and global findings^{7,9,16,18}. The absence of an association
292 with CAO and cigarette smoking might be due to that 50% of the smokers in
293 our study reported a smoking history of ≤ 10 pack-years. Countries with lower
294 smoking rates, such as Malawi and Rwanda, have a lower reported
295 prevalence of COPD^{9,27}. However, the age group 60-69 years who reported
296 the highest smoking rates in this study had the highest prevalence of
297 spirometric obstruction and higher prevalence of both chronic cough and
298 chronic phlegm. The high prevalence of CAO might be due to exposure to air
299 pollutants coming from the large number of factories and cars in the State.

300 A higher educational level was protective against CAO which is compatible
301 with other studies^{10,18,28}. Conversely, a significant association between low
302 socioeconomic status and developing CAO was found in this study, consistent
303 with studies suggesting that low socioeconomic status may be associated with
304 a progression of airflow limitation^{16,29}.

305 We did not observe any association between exposure to biomass fuel and
306 obstruction. This is consistent with the study that included 25 BOLD sites
307 which found that airflow obstruction measured by post-bronchodilator
308 spirometry was not associated with use of solid fuels for cooking or heating³⁰,

309 and findings in other large studies in China^{31,32}. A recent review of studies on
310 COPD and household air pollution concluded that it was not possible to define
311 clear causal links between the two³³.

312 Shortness of breath, one of the most common symptoms of CAO, was
313 significantly higher in those who use biomass fuel for ≥ 6 months. It is
314 possible that this latter group suffer from chronic bronchitis or similar non-
315 obstructive lung diseases. In addition, the finding that only 0.2% reported TB
316 might account for the significant negative association between TB and
317 obstruction, which is in conflict with published literature³⁴. Identification of TB
318 was based on self-reporting and many factors might affect the validity of the
319 answers provided given that TB is a highly stigmatized clinical condition and
320 the proportion reported here may be an underestimate³⁵.

321 A high prevalence of low FVC (62.7%) was identified in this study. BOLD
322 studies in SSA and other studies in resource-poor settings reports similar
323 findings^{9,17}. That 55% of the study population was overweight might partly
324 explain the high level of low FVC⁸.

325 To our knowledge, this is the first study to provide a detailed prevalence
326 estimates of CAO in Sudanese adults using internationally standardised
327 methods and procedures as well as an appropriate sampling technique. We
328 acknowledge our study had limitations. Missing information for a proportion of
329 the study participants limited the cluster-weighted analysis. Furthermore,
330 reasons for exclusion were not recorded, meaning those who were excluded
331 for medical reasons were not separated from those who were excluded for
332 other reasons. Having spirometry readings with no matching questionnaire
333 data for 54 participants and unacceptable spirometry readings from 79
334 participants decreased the sample size and study power.

335 In conclusion, this study found evidence that chronic respiratory disease is a
336 major problem in Sudan and needs to be considered in future public health
337 policies and research. The overall prevalence of CAO in urban Sudan is
338 similar to that found by other BOLD studies in countries with similar smoking
339 rates. However, it is relatively high when compared to other countries in sub-
340 Saharan Africa and the MENA regions. A high prevalence of low FVC was

341 also identified, the aetiology and pathophysiology of which are unknown and
342 require further investigation. These findings suggest the need for
343 strengthening the chronic respiratory disease programs and provision of
344 improved diagnostic and treatment options for CRDs to address
345 underestimation and diagnosis.

346

347 **ACKNOWLEDGEMENTS**

348 This work was supported by Wellcome Trust, UK - grant (085790/Z/08/Z) for
349 the

350 BOLD (Burden of Obstructive Lung Disease) study. Prof. Mortimer received
351 advisory board fees from AstraZeneca outside this work and Dr Nightingale
352 reports grants from Medical Research Council, outside the submitted work.

353 We thank the teams of data collectors and spirometry technicians from Sudan
354 for their hard work during the household survey. We also thank the members
355 of the BOLD Coordinating Centre at the Imperial College London for its
356 assistance with spirometry training, quality control, and data management in
357 the study.

358

359 **CONTRIBUTION STATEMENT**

360 Dr Rana Ahmed wrote the first draft of manuscript, conducted data cleaning,
361 verification, interpretation and analysis of this study.

362 Dr Nada Osman lead the study and contributed to manuscript writing and
363 revision.

364 Dr Bandar Noory coordinated the study, supervised the data collection and
365 contributed to manuscript writing and revision.

366 Dr Rashid Osman revised the spirometry readings, contributed to the writing
367 and revision.

368 Ms Hind Eltigani contributed to data collection, data verification and
369 participated in writing.

370 Ms Hana ElHassan was responsible for the field administration of the overall
371 project. She contributed to the writing and revision.

372 Dr Rebecca Nightingale contributed to the writing and analysis of this
373 manuscript.

374 Dr Andre FS Amaral reviewed and contributed to the writing of this
375 manuscript.

376 Mrs. Jaymini Patel provided the clean data, analysis report and revised the
377 manuscript.

378 Prof. Burney reviewed and contributed to the methodology of the study and
379 reviewed the writing of this manuscript.

380 Prof. Kevin Mortimer supervised, reviewed and contributed to the writing of
381 this manuscript.

382 Prof. Asma El Sony was the principal investigator of the study, she
383 supervised, reviewed and contributed to the writing of this manuscript.

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400 REFERENCES

- 401 1. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and
402 injuries in 204 countries and territories, 1990–2019: a systematic
403 analysis for the Global Burden of Disease Study 2019. *Lancet*.
404 2020;396(10258):1204-1222. doi:10.1016/S0140-6736(20)30925-9
- 405 2. Global Burden of Disease Collaborative Network. Global Burden of
406 Disease Study 2019 (GBD 2019) Results. Seattle, United States:
407 Institute for Health Metrics and Evaluation (IHME), 2020. Global Health
408 Data Exchange. <http://ghdx.healthdata.org/gbd-results-tool>. Published
409 2019.
- 410 3. de-Graft Aikins A, Unwin N, Agyemang C, Allotey P, Campbell C,
411 Arhinful D. Tackling Africa's chronic disease burden: from the local to
412 the global. *Global Health*. 2010;6(August 2016):5. doi:10.1186/1744-
413 8603-6-5
- 414 4. Meghji J, Mortimer K, Agusti A, et al. Improving lung health in low-
415 income and middle-income countries: from challenges to solutions.
416 *Lancet*. 2021;397(10277):928-940. doi:10.1016/S0140-6736(21)00458-
417 X
- 418 5. Salvi S. The silent epidemic of COPD in Africa. *Lancet Glob Heal*.
419 2015;3(1):e6-e7. doi:10.1016/S2214-109X(14)70359-6
- 420 6. Mannino DM. COPD in Africa: the coming storm. *Int J Tuberc Lung Dis*.
421 2013;17(5):572. doi:10.5588/ijtld.13.0157
- 422 7. Awokola BI, Amusa GA, Jewell CP, et al. Chronic obstructive pulmonary
423 disease in sub-Saharan Africa. *Int J Tuberc Lung Dis*. 2022;26(3):232-
424 242. doi:10.5588/ijtld.21.0394
- 425 8. Obaseki DO, Erhabor GE, Awopeju OF, et al. Reduced forced vital
426 capacity in an African population prevalence and risk factors. *Ann Am*
427 *Thorac Soc*. 2017;14(5):714-721. doi:10.1513/AnnalsATS.201608-
428 598OC

- 429 9. Meghji J, Nadeau G, Davis KJ, et al. Noncommunicable lung disease in
430 sub-Saharan Africa a community-based cross-sectional study of adults
431 in urban Malawi. *Am J Respir Crit Care Med.* 2016;194(1).
432 doi:10.1164/rccm.201509-1807OC
- 433 10. Buist a. S, Vollmer WM, McBurnie M a. Worldwide burden of COPD in
434 high- and low-income countries. Part I. The burden of obstructive lung
435 disease (BOLD) initiative. *Int J Tuberc Lung Dis.* 2008;12(7):703-708.
436 doi:S0140-6736(07)61377-4 [pii] 10.1016/S0140-6736(07)61377-4 [doi]
- 437 11. Buist AS, Vollmer WM, Sullivan SD, et al. The Burden of Obstructive
438 Lung Disease Initiative (BOLD): rationale and design. *COPD.*
439 2005;2(2):277-283. doi:10.1081/COPD-200057610
- 440 12. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values
441 from a sample of the general U.S. Population. *Am J Respir Crit Care*
442 *Med.* 1999;159(1):179-187. doi:10.1164/ajrccm.159.1.9712108
- 443 13. Townend J, Minelli C, Harrabi I, et al. Development of an international
444 scale of socio-economic position based on household assets. *Emerg*
445 *Themes Epidemiol.* 2015;12(1):1-11. doi:10.1186/s12982-015-0035-6
- 446 14. Townend J, Minelli C, Mortimer K, et al. The association between
447 chronic airflow obstruction and poverty in 12 sites of the multinational
448 BOLD study. *Eur Respir J.* 2017;49(6).
- 449 15. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values
450 for spirometry for the 3-95-yr age range: The global lung function 2012
451 equations. *Eur Respir J.* 2012;40(6):1324-1343.
452 doi:10.1183/09031936.00080312
- 453 16. Adeloye D, Basquill C, Papana A, Chan KY, Rudan I, Campbell H. An
454 Estimate of the Prevalence of COPD in Africa: A Systematic Analysis.
455 *COPD J Chronic Obstr Pulm Dis.* 2015;12(1):71-81.
456 doi:10.3109/15412555.2014.908834
- 457 17. Burney P, Jithoo A, Kato B, et al. Chronic obstructive pulmonary
458 disease mortality and prevalence: the associations with smoking and
459 poverty—a BOLD analysis. *Thorax.* 2014;69(5):465-473.

- 460 doi:10.1136/thoraxjnl-2013-204460
- 461 18. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the
462 prevalence of COPD (The BOLD Study): a population-based prevalence
463 study. *Lancet*. 2007;370(9589):741-750. doi:10.1016/S0140-
464 6736(07)61377-4
- 465 19. Obaseki DO, Erhabor GE, Gnatiuc L, Adewole OO, Buist SA, Burney
466 PG. Chronic Airflow Obstruction in a Black African Population: Results
467 of BOLD Study, Ile-Ife, Nigeria. *COPD J Chronic Obstr Pulm Dis*.
468 2016;13(1):42-49. doi:10.3109/15412555.2015.1041102
- 469 20. Burney P, Patel J, Minelli C, et al. Prevalence and Population
470 Attributable Risk for Chronic Airflow Obstruction in a Large Multinational
471 Study. *Am J Respir Crit Care Med*. November 2020.
472 doi:10.1164/rccm.202005-1990OC
- 473 21. Al Ghobain M, Alhamad EH, Alorainy HS, Al Kassimi F, Lababidi H, Al-
474 Hajjaj MS. The prevalence of chronic obstructive pulmonary disease in
475 Riyadh, Saudi Arabia: a BOLD study. *Int J Tuberc Lung Dis*.
476 2015;19(10):1252-1257. doi:10.5588/ijtld.14.0939
- 477 22. Daldoul H, Denguezli M, Jithoo A, et al. Prevalence of COPD and
478 tobacco smoking in Tunisia - Results from the BOLD study. *Int J*
479 *Environ Res Public Health*. 2013;10(12):7257-7271.
480 doi:10.3390/ijerph10127257
- 481 23. Denguezli M, Daldoul H, Harrabi I, et al. COPD in Nonsmokers: Reports
482 from the Tunisian Population-Based Burden of Obstructive Lung
483 Disease Study. *PLoS One*. 2016;11(3):e0151981.
484 doi:10.1371/journal.pone.0151981
- 485 24. El Rhazi K, Nejari C, BenJelloun MC, El Biaze M, Attassi M, Garcia-
486 Larsen V. Prevalence of chronic obstructive pulmonary disease in Fez,
487 Morocco: results from the BOLD study. *Int J Tuberc Lung Dis*.
488 2016;20(1):136-141. doi:10.5588/ijtld.15.0029
- 489 25. Hacene Cherkaski H, Khalloufi F, Atoui F, et al. The prevalence of
490 COPD in Annaba, Algeria: Results of the BOLD study. *Eur Respir J*.

- 491 2014;44(Suppl 58).
- 492 26. Ben Abdallah FC, Taktak S, Chtourou A, Mahouachi R, Kheder A Ben.
493 Burden of Chronic Respiratory Diseases (CRD) in Middle East and
494 North Africa (MENA). *World Allergy Organ J.* 2011;4(1 Suppl):S6-8.
495 doi:10.1097/WOX.0b013e3182093cbb
- 496 27. Musafiri S, Joos G, Van Meerbeeck JP. Asthma, atopy and COPD in
497 sub-Saharan countries: the challenges. *East Afr J Public Health.*
498 2011;8(2):161-163.
- 499 28. Mannino DM, Buist AS. Global burden of COPD: risk factors,
500 prevalence, and future trends. *Lancet.* 2007;370(9589):765-773.
501 doi:10.1016/S0140-6736(07)61380-4
- 502 29. Lamprecht B, McBurnie MA, Vollmer WM, et al. COPD in never
503 smokers: Results from the population-based burden of obstructive lung
504 disease study. *Chest.* 2011;139(4):752-763. doi:10.1378/chest.10-1253
- 505 30. André FSA, Jaymini P, Bernet SK, Al E. Airflow obstruction and use of
506 solid fuels for cooking or heating: BOLD results. *Am J Respir Crit Care*
507 *Med.* 2017;182(6):745-751. doi:10.1164/rccm.201003-0326OC
- 508 31. Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic
509 obstructive pulmonary disease in China (the China Pulmonary Health
510 [CPH] study): a national cross-sectional study. *Lancet.*
511 2018;391(10131):1706-1717. doi:[https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(18)30841-9)
512 [6736\(18\)30841-9](https://doi.org/10.1016/S0140-6736(18)30841-9)
- 513 32. Fang L, Gao P, Bao H, et al. Chronic obstructive pulmonary disease in
514 China: a nationwide prevalence study. *Lancet Respir Med.*
515 2018;6(6):421-430. doi:[https://doi.org/10.1016/S2213-2600\(18\)30103-6](https://doi.org/10.1016/S2213-2600(18)30103-6)
- 516 33. Mortimer K, de Oca MM, Salvi S, et al. Household air pollution and
517 COPD: cause and effect or confounding by other aspects of poverty? *Int*
518 *J Tuberc Lung Dis.* 2022;26(3):206. doi:10.5588/ijtld.21.0570
- 519 34. Osman RK, Mortimer K, Bjune G, Sony AI El. Chronic respiratory
520 disease in adults treated for tuberculosis in Khartoum, Sudan. *Public*
521 *Heal Action.* 2016;l(3):199-204.

522 35. Ziyada MM. Exploring tuberculosis Related Stigma in Khartoum-
 523 Sudan: A qualitative study. 2010;(September).
 524 doi:10.13140/RG.2.1.4193.8804

525

526

527

528 **Table 1** Characteristics of all subjects who completed a full BOLD core
 529 questionnaire, including those with and without spirometry results

Variable (n)	n (%)
Age group, years (n=595)	
40–49	226 (38.0)
50–59	200 (33.6)
60–69	108 (18.2)
70+	61 (10.3)
Sex (n=595)	
Male	353 (59.3)
Female	242 (40.7)
Level of education (n=593)	
None	125 (21.1)
Primary school	207 (34.9)
Middle school	69 (11.6)
High school or above	192 (32.4)
Mean years of education (n=595)	6.49 (5.5)
Smoking status (n=595)	
Current smoker	55 (9.2)
Ex-smoker	86 (14.5)
Never smoked	454 (76.3)
Pack-years of smoking (n=595)	
Never smoked	454 (76.3)
0 -10	71 (11.9)
10-20	36(6.1)
≥20	34(5.7)
Biomass exposure (n=532)	
Yes	422 (82.4)
No	90 (17.6)
Farm work for ≥3 months (n=527)	
Yes	126 (23.9)
No	401 (76.1)
Body mass index (n=588)	
Underweight (<18.5)	39 (6.6)
Normal (18.5–24.9)	226 (38.4)
Overweight (25.0–29.9)	189 (32.1)
Obese (≥30)	134 (22.8)
Reported history of tuberculosis (n=595)	
Yes	5 (0.8)

No	590 (99.2)
Reported history of hypertension (n=595)	
Yes	118 (19.8)
No	477 (80.2)
Reported history of diabetes (n=595)	
Yes	54 (9.1)
No	541 (90.9)
Reported history of heart disease (n=595)	
Yes	12 (2.0)
No	583 (98.0)

530

531 **Table 2** Multivariable associations of risk factors with stage 1 or higher CAO
 532 defined using NHANES III (Post-BD FEV₁/FVC < LLN; n=53/516) and Stage 2
 533 or higher CAO defined using NHANES III (Post-BD FEV₁/FVC < LLN and
 534 post-BD FEV₁ < 80% predicted; n=49/516)

Variable	Multivariable association with CAO stage 1 or higher		Multivariable association with CAO stage 2 or higher	
	OR	95% CI	OR	95% CI
Age group, years				
40–49	1.0	-	1.0	-
50–59	2.13	0.84 - 5.41	1.86	0.73 - 4.77
60–69	3.16 *	1.20 - 8.32	2.78*	1.07 - 7.26
70+	1.91	0.60 - 6.10	0.91	0.21 - 3.92
Sex				
Male	1.0	-	1.0	-
Female	1.31	0.61 - 2.84	1.67	0.76 - 3.66
Level of education				
None	1.0	-	1.0	-
Primary school	0.61	0.27 - 1.34	0.62	0.27 - 1.44
Middle school	1.23	0.40 - 3.81	1.03	0.32 - 3.36
High school or above	0.71	0.28 - 1.78	0.69	0.26 - 1.86
Body mass index				
Underweight (<18.5)	1.87	0.66 - 5.30	1.16	0.33 - 4.07
Normal (18.5–24.9)	1.0	-	-	-
Overweight (25.0–29.9)	0.43	0.18 - 1.01	0.37*	0.15 - 0.92
Obese (≥30)	0.35	0.11 - 1.17	0.29*	0.08 - 1.07
Self-reported TB				
No	1.0	-	1.0	0
Yes	0.08*	0.01 - 0.59	0.07*	0.01 - 0.48
Number of people living in	±	±	1.05	0.96 - 1.16
Used firewood				
No	±	±	1.0	-
Yes	±	±	0.58	0.29 - 1.19
Wealth score/Mokken scale	±	±	0.96	0.83 - 1.11

535 **p* <0.05. CAO, Chronic Airflow Obstruction; CI, confidence interval; OR, odds ratio;
 536 FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity ratio; LLN,
 537 lower limit of normal, (±) not included in multivariable analysis

538

539

540

541 **Table 3** Multivariable associations of risk factors with low FVC, defined using
 542 NHANES III reference range (FVC < LLN), n= 315/516

Variable	Multivariable association	
	OR	95% CI
Age group		
40-49	1	-
50-59	0.50*	0.31 - 0.81
60-69	0.29*	0.17 - 0.51
70+	0.25*	0.12 - 0.53
Sex		
Male	1	-
Female	0.78	0.48 - 1.24
Body Mass Index (kg/m ²)		
Underweight (BMI<18.5)	0.95	0.43 - 2.07
Normal (BMI 18-25)	1	-
Overweight (BMI 25-30)	1.39	0.85 - 2.27
Obese (BMI >30)	1.55	0.87 - 2.80
Packs-year of smoking		
Never	1	-
0-10	1.09	0.59 - 2.02
10-20	2.45	0.88 - 6.86
≥20	1.00	0.47 - 2.11
Wealth score/Mokken scale	0.97	0.90 -1.04

**p* <0.05. CI, confidence interval; OR, odds ratio; FVC, forced vital capacity ratio;
 LLN, lower limit of normal

543

544

545

546

547

548

549

550

551

552

553

554

555 **Figure 1** Participant flow diagram

556 **Figure 2** Estimated Population Prevalence of chronic airflow obstruction by
557 age and sex using National Health and Nutrition Examination Survey
558 reference ranges (NHANES) for the Sudanese population in participants
559 completing standard American Thoracic Society spirometry (n=516). The
560 upper graph represents the prevalence of Stage 1 or higher CAO (Post-BD
561 FEV1/FVC < LLN) and the lower graph represents the prevalence of Stage 2
562 or higher CAO (Post-BD FEV1/FVC < LLN and post-BD FEV1 < 80%
563 predicted).

564